|
| 阿仑膦酸钠治疗骨折后骨质疏松临床观察 |
| Clinical observation of alendronate sodium in the treatment of osteoporosis after fracture |
| |
| DOI：10.3969/j.issn.1006-7108.2020.08.016 |
| 中文关键词: 阿仑膦酸钠 重症骨折继发骨质疏松 临床疗效 |
| 英文关键词:alendronate osteoporosis secondary to severe fracture clinical efficacy |
| 基金项目: |
|
| 摘要点击次数: 992 |
| 全文下载次数: 486 |
| 中文摘要: |
| 目的 观察阿仑膦酸钠治疗重症骨折继发骨质疏松的临床疗效。方法 选取2017年8月至2018年11月空军特色医学中心收治的60例重症骨折继发骨质疏松患者作为研究对象，根据入院的基偶顺序分别设为对照组和治疗组，各30例。对照组在骨折三个月后给予常规治疗，治疗组则在骨折三个月后在对照组的治疗基础上给予口服阿仑膦酸钠治疗，两组均治疗三个月，观察比较两组患者临床疗效，检测治疗前后两组患者骨代谢标志物I型胶原交联氨基端肽(NTXI)、I型胶原交联羧基端肽(CTXI)、抗酒石酸酸性磷酸酶5b(TRACP5b)和血骨钙素(BGP)、骨密度（bone mineral density, BMD）、骨碱性磷酸酶（BALP）。结果 治疗前两组患者的NTXI、CTXI、TRACP5b、 BGP、BMD和BALP等均无显著性差异（P>0.05）。治疗后，治疗组的总有效率为93.3%明显高于对照组的70.0%（P<0.05）；治疗组的NTXI、CTXI、TRACP5b、BGP、BMD和BALP较对照组均明显改善，差异具有统计学意义（P<0.05）。结论 阿仑膦酸钠治疗重症骨折继发骨质疏松的临床疗效显著，值得临床推广。 |
| 英文摘要: |
| Objective To observe the clinical efficacy of alendronate in the treatment of severe fracture secondary to osteoporosis. Methods Sixty patients with severe fracture secondary to osteoporosis admitted to our hospital from August 2017 to November 2018 were enrolled in the study. The order of admission was set as the control group and the treatment group, 30 cases each group. The control group received routine treatment three months after the fracture, and the treatment group was treated with alendronate sodium on the basis of the treatment of the control group after three months of fracture. The two groups were treated for three months. The clinical effects of the two groups were observed and compared.The levels of bone metabolism markers type I collagen cross-linked amino terminal peptide (NTXI), type I collagen cross-linked carboxy terminal peptide (CTXI), tartrate-resistant acid phosphatase 5b (TRACP5b) and blood bone Calcium (BGP), bone mineral density (BMD) and bone alkaline phosphatase (BALP) before and after treatment were measured.Results There were no significant differences in NTXI, CTXI, TRACP5b, BGP, BMD and BALP between the two groups before treatment (P>0.05). After treatment, the total effective rate of the treatment group was 93.3% significantly higher than that of the control group (70.0%,P<0.05). The NTXI, CTXI, TRACP5b, BGP, BMD and BALP in the treatment group were significantly improved compared with the control group, and the difference was statistically significant (P<0.05). Conclusion The clinical efficacy of alendronate in the treatment of severe fracture secondary to osteoporosis has a significant clinical effect and it is worth clinical promotion. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|